Member testimonials
Not all questions we have about MS treatment can be answered by rigorous clinical trials. Trials provide directions. Registries provide wisdom of real life practice. Therefore we are part of MSBase.
Prof Eva Havrdova, Czech Republic
MSBase provided me with a well-developed evolving platform for scientific research in collaboration with international, well-recognised Multiple Sclerosis experts.
Dr Raed Alroughani, Kuwait
The MSBase Registry has become a major source of new knowledge. Indeed, using data coming from the registry and taking advantage or the more than 30,000 patient records, important studies based on 'real-life' data have been presented at ECTRIMS, and an impressive number of publications in high-impact medical journals have been published. This constitutes an important source of new knowledge, and testifies to the capacity of the international MS community to share and exploit data derived from current clinical practice. This MS Registry is now an incontournable component of the MS global academic effort.
Pierre Duquette, Canada
Being a part of MSBase enables me to contribute to this global commitment and effort to capture and record information about people with MS in everyday clinical practice, that builds an ever expanding foundation of knowledge. I can see that this knowledge will help inform the delivery of the safest, most effective and highest quality of care, now and in the future. It is exciting to learn from and be inspired by others questions and answers in their studies. Joining the dots together you see answers emerging to questions, and it is very satisfying to be a part of that.
Jodi Haartsen, Australia
I have watched the MSBase Registry go from strength to strength since I first started collaborating with the Registry in 2010. Seeing significant scientific outputs come from MSBase, those that have shaped MS clinical management and care, including care of pregnant women with MS has been an absolute highlight. Contributing to this effort is a genuine privilege.
A/Prof Vilija Jokubaitis, Australia
"On behalf of the members of the Zuyderland Hospital in the Netherlands, I want to underline the huge importance of the scientific output of the MSBase Registry for clinical practice. The MSBase Registry generates real-life data of the evolution of MS with and without immunomodulation and of the separate MS disease types. Moreover it generates important epidemiological data."
Prof Raymond Hupperts, Netherlands
MSBase has allowed us to take local and national observations on the epidemiology of MS and study them in a truly global manner.
Prof Bruce Taylor, Australia
MSBase gave us the unique possibility to showcase some innovative proof-of-concepts using cutting edge technologies like artificial intelligence and federated learning. In doing so, MSBase confirms their pioneering role in the real-world MS data ecosystem.
Liesbet M. Peeters, Belgium
To become a member of MSBase opened many research opportunities to my centre – Hospital de S. Joao - the only portuguese center entering the registry up to now. iMed is very important, we access it in each consultation to see the patient’s evolution and alert to eventual redflags. To be aware how our local cohort compares with the MSBase whole registry is very reassuring and a relevant issue of this collaborative research.
Maria Jose Sa, Portugal
As a member of the Medical Leadership Group, I have seen how MSBase advances global multiple sclerosis care by continuously updating knowledge, generating high quality real world data, and building a trusted network of professionals to share questions, insights, and solutions for patients. This includes a strong focus on sex and gender informed analytics and richer data on women’s health across the MS journey, helping close evidence gaps and guide more equitable care.
Sara Eichau, Spain
MSBase has served as a unique resource on the quest of translating data into evidence. Alongside large national registries and high-quality cohorts, it has enabled us to generate new knowledge, which has been guiding the use of disease modifying therapies across ages, multiple sclerosis phenotypes, including over the long term and in scenarios that can not be studied in randomised trials. It has provided us with an instrumental data-space to apply, adopt or develop rigorous analytical methods. I am excited to see MSBase apply the learned experience beyond multiple sclerosis, in the research of rarer neuroimmunological diseases.
Prof Tomas Kalincik, Australia
Membership
Take part, make a difference!
Neurologists, take part by joining a collaboration dedicated to making a difference to the lives of patients with MS and other neuro-immunological diseases.